Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06206837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from Pfizer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Results posted: Sep 30, 2026
    • Study completion pushed from Sep 7, 2026 to May 25, 2027
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 17 to 29
    • Study sites revised (58)
  2. Study sites: 54 to 58
    • Study completion date: Mar 6, 2026 to Sep 7, 2026
    v14
  3. Study sites revised (54)v13
  4. Enrollment target: 65 to 71
    • Study sites revised (54)
    v12
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 57 to 54
    • Primary completion date: Aug 14, 2025 to Sep 5, 2025
    • Study completion date: Feb 13, 2026 to Mar 6, 2026
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 54 to 57v10
  2. Study sites: 34 to 54v9
  3. Study sites: 11 to 34v8
  4. Re-verified, no change to tracked fieldsv7
  5. Study sites: 10 to 11v6
  6. Study sites: 9 to 10v5
  7. Study sites: 8 to 9v4
  8. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 5 to 8
    • Primary completion date: May 18, 2026 to Aug 14, 2025
    • Study completion date: Nov 17, 2026 to Feb 13, 2026
    • Start date changed from estimate of Feb 29, 2024 to Feb 19, 2024
  9. Start date: Jan 8, 2024 to Feb 29, 2024
    • Study sites: 0 to 5
    • Secondary endpoints: details revised at 2 of 17 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Trial Details
NCT Number NCT06206837
Lead Sponsor Pfizer
Collaborators: Arvinas Estrogen Receptor, Inc.
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov